Komal Jhaveri, MD, FACP, discusses the use of trastuzumab biosimilars in breast cancer.
Komal Jhaveri, MD, FACP, a section head within the breast medicine service at Memorial Sloan Kettering Cancer Center, discusses the use of trastuzumab (Herceptin) biosimilars in breast cancer.
The trastuzumab biosimilar data, presented by Hope Rugo, MD, showed that the biosimilar trial designs for bioequivalence were met when compared with reference trastuzumab, explains Jhaveri.
The purpose of biosimilars in breast cancer is to have similar efficacy of original trastuzumab for patients, without the financial toxicity many approved agents cause, says Jhaveri. The financial toxicity can be very difficult for certain patient populations, especially in countries outside of the United States, concludes Jhaveri.